Clinical and economic impact of compression in the acute phase of deep vein thrombosis by Amin, E. E. et al.
  
 University of Groningen
Clinical and economic impact of compression in the acute phase of deep vein thrombosis
Amin, E. E.; Joore, M. A.; ten Cate, H.; Meijer, K.; Tick, L. W.; Middeldorp, S.; Mostard, G. J.
M.; ten Wolde, M.; Van den Heiligenberg, S. M.; Van Wissen, S.
Published in:
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
DOI:
10.1111/jth.14163
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Amin, E. E., Joore, M. A., ten Cate, H., Meijer, K., Tick, L. W., Middeldorp, S., ... ten Cate-Hoek, A. J.
(2018). Clinical and economic impact of compression in the acute phase of deep vein thrombosis.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 16(8), 1555-1563. https://doi.org/10.1111/jth.14163
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
ORIGINAL ARTICLE
Clinical and economic impact of compression in the acute
phase of deep vein thrombosis
E . E . AMIN ,*†‡ M. A. JOORE ,† H. TEN CATE ,*‡ K . ME I J ER ,§ L . W. T ICK , ¶ S . MIDDELDORP ,**
G . J . M . MOSTARD,†† M. TEN WOLDE ,‡‡ S . M. VAN DEN HE IL IGENBERG,§§ S . VAN WISSEN , ¶ ¶
M. H. W. VAN DE POEL ,*** S . V I LLALTA ,††† E . H . SERNE,‡‡‡ H. -M. OTTEN ,§§§ E . H . KLAPPE , ¶ ¶ ¶
P . PRANDONI**** and A . J . T EN CATE-HOEK*‡
*Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University; †Department of Clinical Epidemiology and
Medical Technology Assessment, School for Public Health and Primary Care, Maastricht University; ‡Department of Internal Medicine,
Maastricht University Medical Center, Maastricht; §Department of Hematology, University of Groningen, University Medical Center
Groningen, Groningen; ¶Department of Internal Medicine, Maxima Medical Center Eindhoven, Eindhoven; **Department of Vascular
Medicine, Academic Medical Center Amsterdam, Amsterdam; ††Department of Internal Medicine, Zuyderland Medical Center, Heerlen;
‡‡Department of Internal Medicine, Flevoziekenhuis, Almere; §§Department of Internal Medicine, Westfriesgasthuis, Hoorn; ¶¶Department of
Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam; ***Department of Internal Medicine, Laurentius Hospital, Roermond, the
Netherlands; †††Department of Internal Medicine, Ca Foncello University Hospital, Treviso, Italy; ‡‡‡Department of Internal Medicine, VU
Medical Center; §§§Department of Internal Medicine, MC Slotervaart, Amsterdam; ¶¶¶Department of Internal Medicine, University Medical
Center Nijmegen, Nijmegen, the Netherlands; and ****Arianna Foundation on Anticoagulation, Bologna, Italy
To cite this article: Amin EE, Joore MA, ten Cate H, Meijer K, Tick LW, Middeldorp S, Mostard GJM, ten Wolde M, van den Heiligenberg SM,
van Wissen S, van de Poel MHW, Villalta S, Serne EH, Otten H-M, Klappe EH, Prandoni P, ten Cate-Hoek AJ. Clinical and economic impact of
compression in the acute phase of deep vein thrombosis. J Thromb Haemost 2018; 16: 1555–63.
Essentials
• The value of compression therapy in acute phase of
deep vein thrombosis is still unclear.
• Patients with deep vein thrombosis received acute com-
pression hosiery, bandaging, or none.
• Acute compression reduces irreversible skin signs
related to post thrombotic syndrome.
• Compression hosiery may be the preferred choice for
the acute phase
Summary. Background: The effectiveness of compression
therapy in the acute phase of deep vein thrombosis
(DVT) is not yet determined. Objectives: To investigate
the impact of compression therapy in the acute phase of
DVT on determinants of the Villalta score, health-related
quality of life (HRQOL), and costs. Patients/Methods:
Eight hundred and sixty-five patients with proximal DVT
(substudy of the IDEAL DVT study) received, immedi-
ately after DVT diagnosis, either no compression,
multilayer bandaging, or hosiery. In the acute phase and
3 months after diagnosis, HRQOL was determined by use
of the EQ-5D, SF6D, and VEINES-QoL intrinsic method
(VEINES-QoLint). At 3 months, signs and symptoms
were assessed for the total and separate items of the Vil-
lalta score, and healthcare costs were calculated. Results:
The compression groups had lower overall objective Vil-
lalta scores than the no-compression group (1.47 [stan-
dard deviation (SD) 1.570] and 1.59 [SD 1.64] versus 2.21
[SD 2.15]). The differences were mainly attributable to
irreversible skin signs (induration, hyperpigmentation, and
venectasia) and pain on calf compression. Subjective and total
Villalta scores were similar across groups. Differences in
HRQOL were only observed at 1 month; HRQOL was better
for hosiery (EQ-5D 0.86 [SD 0.18]; VEINES-QoLint 0.66
[SD 0.18]) than for multilayer compression bandaging
(EQ-5D 0.81 [SD 0.23; VEINES-QoLint 0.62 [SD 0.19]).
Mean healthcare costs per patient were €417.08
(€354.10 to €489.30) for bandaging, €114.25 (€92.50 to
€198.43) for hosiery, and €105.86 (€34.63 to €199.30)
for no compression. Conclusions: Initial compression
reduces irreversible skin signs, edema, and pain on calf
compression. Multilayer bandaging is slightly more
effective than hosiery, but has substantially higher costs,
without a gain in HRQOL. From a patient and eco-
nomic perspective, compression hosiery would be pre-
ferred when initial compression is applied. Trial
registration: IDEAL DVT study ClinicalTrials.gov num-
ber, NCT01429714.
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Introduction
Deep vein thrombosis (DVT) is a potential debilitating
and life-threatening disease, with an annual incidence of
1–2 per 1000 people [1]. Complaints related to DVT can
vary from mild to severe, with DVT recurrence and pul-
monary embolism being the most severe consequences [2].
The long-term complication is known as post-thrombotic
syndrome (PTS), and develops in 20–50% of patients
within 2 years after DVT diagnosis [3,4]. PTS is an irre-
versible condition that comprises a combination of
patient-reported symptoms such as pain and cramps, and
objective signs such as edema and venous ulcers. The
severity of each of the signs and symptoms is assessed
with the Villalta score. According to the current consen-
sus ISTH scoring method, a sum score of ≥ 5 at least
6 months after DVT is considered to show that PTS is
present [5]. It has been shown that quality of life is
reduced in patients with DVT in general [6,7], and in PTS
patients in particular [8]. Moreover, DVT complicated by
PTS is associated with higher costs than DVT without
PTS [9,10].
The main, although disputed, form of preventive ther-
apy for PTS is the use of elastic compression stockings
(ECS) (class III, ankle pressure of 40 mmHg) for a per-
iod of up to 2 years following DVT [3,4,11]. Generally,
ECS are applied as soon as leg edema is resolved, which
usually takes 2–6 weeks. Currently, there is no consensus
regarding what the preferred mode of treatment is in the
time frame between DVT diagnosis and ESC application.
There are three possible approaches to bridge the acute
phase: no compression, the application of multilayer
compression bandages, or the use of thigh-high compres-
sion hosiery (Mediven Struva 35 mmHg). Up to now,
only a limited number of, mainly smaller, studies have
explored the general effects of compression therapy in
the acute phase of DVT. A randomized controlled trial
with 69 patients compared the effect of multilayer ban-
daging with no compression, and found an improvement
in clinical symptoms and a decrease in leg circumference
7 days after intervention, but no effect was found after
1 month and 3 months, or in relation to PTS after
1 year [12]. Beneficial effects of compression therapy
immediately after thrombosis were observed by others
[13]. A study in 53 patients that compared compression
with inelastic bandaging or ECS in addition to daily
walking exercise vsersus no compression combined with
bed rest showed that, at 9 days, quality of life was sig-
nificantly better in the compression group. Patients who
received compression reported significantly less pain and
swelling. [14].
On the basis of the outcomes of these few studies, com-
pression in the acute phase of DVT seems to have benefi-
cial effects in terms of diminished signs and symptoms;
however, conclusive answers are lacking, as the studies
were relatively small. Therefore, the current study was
aimed at comparing the effects of no compression, multi-
layer bandaging and compression hosiery in the acute
phase of DVT on the separate items as well as the overall
Villalta score. In addition, the present study aimed to
assess the impact of acute compression therapy on quality
of life, and to estimate the initial healthcare costs related
to acute compression therapy following DVT diagnosis.
Methods
Study design and population center
This study was an a priori-planned substudy of the
IDEAL DVT study, which has been described in detail
previously [15]. In short, the IDEAL DVT study was a
multicenter randomized controlled trial that started in
April 2011 and was concluded in July 2017. The study
involved 865 patients with objectively confirmed proximal
DVT without venous insufficiency or previous DVT from
12 medical centers across the Netherlands and two in
Italy.
The study compared individualized duration of ECS
use with standard long-term (24 months) duration. Three
prespecified treatment protocols that were agreed upon
before study start described which form of compression
therapy was applied in the acute phase of DVT in each
individual center in the time frame between DVT diagno-
sis and the start of ECS use [16]. All included patients
received thigh-high short stretch multilayer compression
bandaging applied by trained healthcare professionals,
thigh-high elastic compression hosiery (Mediven Struva
35 mmHg), or no compression; this initial treatment was
not randomized, but was allocated according to the cen-
ters’ prespecified treatment protocols. The randomization
for the IDEAL DVT study was stratified by center in
order to ensure an equal distribution of initial treatments.
If compression was initiated, this was performed within
24 h of DVT diagnosis. A week prior to the outpatient
clinic visits, the patients filled out a questionnaire on
quality of life and costs. The first (baseline) questionnaire
was filled out within a week after the inclusion. The lan-
guage of the overall questionnaire was Dutch for the
Dutch centers and Italian for the Italian centers.
Outcomes
Determinants of the Villalta score at 3 months after DVT
were assessed. These included five patient-rated symptoms
(pain, cramps, heaviness, paresthesia, and itching) and six
physical signs (pretibial edema, skin induration, hyperpig-
mentation, pain during calf compression, venous ectasia,
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and redness). All items were graded for intensity on a 4-
point scale: 0 points when there were no deviations from
normal, 1 point if the signs or symptoms were mild, 2
points if they were moderate, and 3 points if they were
severe. Symptoms of the subjective Villalta score were
rated and filled out by patients in the questionnaire. The
objective items were assessed and filled out at each study
visit by a medical doctor or a research nurse in the case
report form.
Health-related quality of life (HRQOL) was assessed in
the acute phase of DVT (1 week after inclusion) and
3 months after DVT diagnosis. HRQOL was determined
with two generic questionnaires and one disease-specific
questionnaire: the EQ-5D, the Short Form Health Survey
version 2 (SF36), and the disease-specific Venous Insuffi-
ciency Epidemiological and Economic Study (VEINES-
QoL). The EQ-5D covers five dimensions of generic
HRQOL (mobility, self-care, usual activity, pain, and
anxiety). Health state preferences, expressed as utility
scores, are calculated with a scoring function based on
the preferences of a general public (2997 respondents
from the UK) and scores on each item [17]. The range of
the score is  0.59 to 1, where  0.59 suggests a health
state worse than death, 0 refers to death, and 1 indicates
perfect health. The SF36 consists of 36 questions covering
several health domains: physical functioning, physical role
functioning, emotional role functioning, social role func-
tioning, mental health, bodily pain, vitality, and general
health perceptions. A utility score derived from the SF36,
the SF6D, was calculated [18]. On the basis of the litera-
ture, a difference of 0.076 in EQ-5D scores and a differ-
ence of 0.041 in SF6D scores were considered to be
clinically relevant differences [19].
The VEINES-QoL contains 26 items on the following
topics: DVT-related symptoms, limitations in daily activi-
ties, time of day when the leg complaint is of greatest
intensity, changes in leg complaints over the last year,
and the psychological impact of the leg complaints [20].
The VEINES-Qol average score was calculated on the
basis of the intrinsic method (VEINES-QoLint) as recom-
mended by Bland et al. [21], whereby each item score (i)
is recoded to (i – 1)/(k – 1), with k referring to the num-
ber of categories. Based on this formula, each item’s score
has a value between 0 and 1, and the average is the final
score. This intrinsic method makes it possible to compare
average quality of life scores with other quality of life
scores. For all quality of life instruments, a higher score
suggests better quality of life.
The following cost domains were estimated: visits (in-
cluding transportation costs) to the general practitioner,
general practice center out of hours care, or medical spe-
cialist, the use of painkillers, home care nursing demands,
and costs of compression material use. Unit costs were
multiplied by the patient-reported frequency of resource
use, with recall periods of 4 weeks for nursing and
8 weeks for other items (reported at 3 months after DVT
diagnosis), and divided by the total number of patients
per group. Unit costs were based on the guidelines on
healthcare costs drafted by the Dutch Health Authority
[22]. The costs of the compression bandages were based
on amounts as indicated in the Dutch G-standard March
2017 [23]. The costs of the compression hosiery were €25
to €55 per item [24].
Statistical analysis
All statistical analyses were performed with SPSS ver-
sion 23, with a P-value of ≤ 0.05 being considered to be
statistically significant. The association between different
compression strategies and separate signs and symptoms
forming the Villalta score were analyzed, as were the total
objective, total subjective and the complete Villalta scores,
by the use of ANCOVA for comparison of multiple groups
and regression analysis for two-group comparisons. Split
plot analysis of variance for repeated measures was per-
formed for assessment of the time effect on quality of life
scores. Analyses were adjusted for center and baseline
variables that differed significantly among groups. Costs
were bootstrapped to obtain 95% credibility intervals.
Sensitivity analyses were performed with complete data.
Subanalysis with regard to assessment of signs and symp-
toms was performed in patients with iliofemoral DVT.
All analyses were also performed with the bandaging
group and hosiery group taken together as one compres-
sion group.
Results
The percentages of missing data attributable to with-
drawals, loss to follow-up, disease and late exclusion were
4.3%, 1.4%, 2.8%, and 1.0%, respectively. Analyses with
complete cases and cases with some missing data on the
items showed no statistically significant difference. There-
fore, imputation of missing data was not performed.
Subject characteristics
The study population consisted of 865 patients. The aver-
age inclusion date was 18.4  12 days after DVT diagno-
sis. A total of 668 patients (78.0%) received initial
compression, of whom 415 (48.5%) were in the multilayer
bandaging group, and 253 (29.6%) were in the compres-
sion hosiery group. However, 16 of 253 (6.3%) patients
in the hosiery group required multilayer bandaging
because of leg complaints. One hundred and eighty-eight
patients (21.9%) received no initial compression. Table 1
shows the baseline characteristics for the study popula-
tion. Overall, the mean age was 57.2  15.1 years. The
percentage of male patients was 58.2%. The average body
mass index was 27.9  5.2 kg m2. DVT located in the
left leg was seen in 451 (52.7%) of patients. Previous con-
tralateral DVT was seen in 81 (9.5%) patients. The
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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baseline characteristics across groups were mostly similar;
a statistically significant difference among the groups was
found only with regard to the nature and location of
DVT. In the no-compression group, 108 (57.4%) patients
had unprovoked DVT, in comparison with 296 (71.3%)
in the multilayer bandaging group and 175 (69.2%) in the
hosiery group (P = 0.017). DVT was located in the com-
mon femoral vein in 33.5% of patients in the no-compres-
sion group, as compared with 19.0% in the multilayer
bandaging group and 16.6% in the hosiery group
(P < 0.001).
Signs and symptoms
Figure 1 and Table 2 show the Villalta scores at
3 months after DVT diagnosis. The total Villalta score,
the total subjective Villalta score and all individual items
constituting the subjective part were not significantly dif-
ferent among groups. Significant differences were
observed for the objective part of the Villalta score; the
total objective score in the compression groups com-
bined (1.52  1.59, P < 0.001) was lower than that in
the no-compression group (2.21  2.15) The scores for
the separate compression groups were also lower than
that in the no-compression group: 1.47  1.57 in the
multilayer bandaging group (P < 0.001), and 1.59  1.64
in the hosiery group (P < 0.001). Additionally, statisti-
cally significant differences between the compression
group and the no-compression group were seen for
mainly irreversible signs, i.e. skin induration, hyperpig-
mentation, and venectasia, and for pain upon calf com-
pression. Those with bandaging had statistically
significant lower scores on the objective items skin
induration and hyperpigmentation than those with
hosiery (respectively: 0.04  0.27 versus 0.15  0.44,
P = 0.002; and 0.11  0.37 versus 0.20  0.46,
P = 0.028).
The results of the subgroup analysis using only data of
patients with iliofemoral thrombosis were in line with the
results for the entire population. There were no differ-
ences in the total Villalta score or the subjective part of
the Villalta score. The total objective part was signifi-
cantly lower in the compression groups than in the no-
compression group (1.78  2.17 versus 2.20  2.17,
P = 0.025). The efficacy of compression was entirely
based on multilayer compression bandaging. In this
group, a significantly lower total objective Villalta score
with fewer irreversible skin signs, i.e. indurations, hyper-
pigmentation, and venectasia, was observed than in the
no-compression group (1.52  160 versus 2.2  2.17,
P = 0.017) and the hosiery group (2.25  1.72,
P = 0.158).
Quality of life
Table 3 shows the quality of life scores in the acute phase
and at 3 months after DVT. There were no statistically
significant differences in HRQOL for all compression ver-
sus no compression. In the acute phase, however, the
hosiery group had statistically significantly higher scores
than the bandaging group on the EQ-5D (0.86  0.18
versus 0.81  0.23, P = 0.015) and the VEINES-QoLint
(0.66  0.18 versus 0.62  0.19, P = 0.030). Three
months after DVT, no statistically significant differences
were observed. Split plot analysis of variance for repeated
measures showed no statistically significant difference
over time (SF6D, P = 0.470; EQ-5D, P = 0.263; and
VEINES-QoLint, P = 0.136). This means that, if the two
time points are combined, no differences in the compres-
sion groups exist.




group (N = 415)
Compression hosiery
group (N = 253)
No-compression




57.2 (15.1) 58.0 (15.5) 56.5 (14.1) 56.4 (15.6) 0.307
Male, n (%) 498 (58.2) 244 (58.8) 148 (58.5) 106 (56.4) 0.850
BMI (kg m2) (SD) 27.9 (5.2) 28.1 (5.0) 27.9 (5.1) 27.7 (5.8) 0.646
DVT in left leg, n (%) 451 (52.7) 223 (53.7) 128 (50.6) 100 (53.2) 0.726
Previous contralateral
DVT, n (%)
81 (9.5) 40 (9.6) 19 (7.6) 22 (11.7) 0.169
Unprovoked DVT,
n (%)
579 (67.6) 296 (71.3) 175 (69.2) 108 (57.4) 0.017
DVT location, n (%)
Popliteal 421 (49.2) 224 (54.0) 130 (51.4) 67 (35.6) < 0.001
Femoral 236 (27.6) 108 (26.0) 80 (31.6) 48 (25.5)
Common femoral 184 (21.5) 79 (19.0) 42 (16.6) 63 (33.5)
Unknown 15 (1.6) 4 (1.0) 1 (0.4) 10 (5.3)
BMI, body mass index; DVT, deep vein thrombosis; SD, standard deviation. *v2 test for categorical variables; one-way ANOVA for continuous
variables. P-values refers to differences among groups or the difference in distribution of thrombus location among groups. Values in bold indi-
cate statistical significance.
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Costs
Healthcare costs in the compression groups are shown in
Table 4. The mean total costs per patient were highest for
the bandaging group (€417.08, 95% confidence interval
[CI] €354.10 to €489.30), followed by the hosiery group
(€114.25, 95% CI €92.50 to €198.43); the costs were low-
est for the no-compression group (€105.86, 95-
% CI €34.63 to €199.30). The differences in costs across
groups were mainly attributable to costs related to com-
pression material use and home care nursing demands,
which were both highest in the bandaging group and low-
est in the no-compression group.
Discussion
Compression in the acute phase of DVT reduces the occur-
rence of pain on calf compression, and the incidence of
hyperpigmentation, venectasia, and skin induration, which
are irreversible skin signs that are associated with PTS.
Consequently, the objective part of the Villalta score was
significantly decreased in patients who received initial com-
pression therapy. These effects, although small in absolute
terms, were significantly more pronounced in the group of
patients who received multilayer bandaging. No differences
among groups were seen with regard to the subjective items
of the Villalta score and the sum total Villalta score.
Villalta score at 3 months after DVT



















































































Fig. 1. Total Villalta scores and the separate items of the Villalta score at 3 months after diagnosis of deep vein thrombosis






























Mean SD Mean SD P-value Mean SD P-value Mean SD P-value P-value
Total objective
Villalta
1.52 1.59 2.21 2.15 < 0.001 1.47 1.57 < 0.001 1.59 1.64 < 0.001 1.000
Edema 0.50 0.69 0.64 0.79 0.163 0.53 0.73 0.222 0.45 0.62 0.018 0.513
Skin induration 0.08 0.35 0.24 0.54 < 0.001 0.04 0.27 < 0.001 0.15 0.44 0.067 0.002
Hyperpigmentation 0.14 0.41 0.28 0.56 < 0.001 0.11 0.37 < 0.001 0.20 0.46 0.141 0.028
Venous ectasia 0.47 0.71 0.62 0.76 < 0.001 0.51 0.79 0.138 0.40 0.55 0.002 0.149
Redness 0.29 0.55 0.24 0.55 0.154 0.27 0.54 1.000 0.33 0.56 0.461 0.649
Pain on calf
compression
0.03 0.20 0.19 0.52 < 0.001 0.01 0.11 < 0.001 0.07 0.30 < 0.001 0.076
Total subjective score 2.54 2.74 2.29 2.49 0.162 2.46 2.55 1.000 2.65 3.03 0.556 1.000
Heaviness 0.60 0.86 0.59 0.77 0.652 0.60 0.83 1.000 0.62 0.90 1.000 1.000
Pain 0.67 0.93 0.59 0.85 0.354 0.68 0.93 0.924 0.67 0.95 1.000 1.000
Cramps 0.40 0.72 0.32 0.65 0.086 0.37 0.66 1.000 0.45 0.80 0.263 0.463
Itching 0.40 0.68 0.38 0.71 0.501 0.37 0.65 1.000 0.44 0.74 1.000 0.649
Tingling 0.47 0.71 0.41 0.67 0.210 0.45 0.69 1.000 0.49 0.74 0.645 1.000
Total Villalta score 4.05 3.34 4.50 3.68 0.168 3.94 3.08 0.154 4.25 3.72 1.000 0.734
SD, standard deviation. Analyses were adjusted for baseline differences and patient center. Values in bold indicate statistical significance.
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The exact pathophysiology of PTS is not yet known;
however, it is assumed that, in the acute phase, venous
hypertension caused by thrombus obstruction and subse-
quent inflammation and edema are central features.
External compression reduces the vein diameter and
improves venous flow velocity, thereby improving venous
outflow and reducing edema and inflammation. There-
fore, compression in the acute phase may reduce inflam-
mation and secondary skin changes associated with PTS
[25–27], as is also suggested by our results.
It might be argued whether these small differences are
clinically relevant. In absolute terms, the majority of
patients had low Villalta scores, with no or minimal signs
and symptoms. However, if the percentages of moderate
and severe signs between groups are compared, then the
differences become prominent. As these differences
involve irreversible skin signs, they may be considered to
be clinically relevant. Overall, patients experienced rela-
tively few complaints. This lack of contrast between treat-
ment groups for the subjective part of the Villalta score
was reflected in the similar outcomes for quality of life
assessments. In the initial phase, however, HRQOL was
significantly better for hosiery than for bandaging.
The costs and burdens related to multilayer bandaging
are higher than those related to no compression and hosi-
ery. The question is, what amount of expenditure and dis-
comfort is justified in relation to the outcome? Therefore,
it is of the utmost importance to be able to identify
patients at the highest risk, as patients at risk for PTS
constitute a heterogeneous group.
So far, only a few studies have assessed the merits of
compression in the acute phase. The numbers of partici-
pants were rather small, i.e. 69, 53 and 73 patients [12]
[14,28]. Moreover, those studies did not assess the signs
and symptoms of PTS individually. Despite the men-
tioned limitations, they too found some beneficial effects
of compression in the acute phase of DVT.
The strengths of our study are its size and its multicen-
ter nature, as it involved both academic and non-aca-
demic centers, and the fact that quality of life and cost
aspects were also assessed. A limitation of our study
design is the lack of randomization of patients for the
three preventive options. However, each center offered
the same therapy to all patients from that center, so the
choice of intervention could be considered to be quasi-
randomized. Furthermore, analyses were adjusted for cen-
ter and baseline differences between treatment groups.
It is important to determine which of the three men-
tioned options (multilayer bandaging, compression hosi-
ery, or no initial compression) should be chosen, not only
because their effects on clinical symptoms might differ,
but also because the costs related to each option can vary
substantially. Multilayer bandaging requires the help of
(para)medical professionals and more medical materials,
owing to regular redressing, than compression hosiery,
which patients need to purchase only once and can apply
by themselves.
We found that, for the subgroup of patients with iliofe-
moral DVT, that compression hosiery was not effective,
but that multilayer bandaging provided a significant
reduction in irreversible skin signs. For the specific sub-
group of patients with iliofemoral DVT, the costs and
burdens of multilayer bandaging might therefore be
weighted differently and favour multilayer bandaging.
In conclusion, there are significant reductions in ir-
reversible signs, edema and pain on calf compression


























Mean SD Mean SD P-value Mean SD P-value Mean SD P-value P-value
Acute phase of
DVT
N = 171 N = 385 N = 218
VEINES-
QoLint
0.64 0.18 0.62 0.17 0.553 0.62 0.19 1.000 0.66 0.18 0.192 0.030
SF6D 0.62 0.06 0.62 0.06 0.809 0.62 0.06 1.000 0.61 0.06 0.758 1.000




N = 668 N = 188 N = 415 N = 253
VEINES-
QoLint
0.73 0.16 0.72 0.16 0.657 0.72 0.16 1.000 0.74 0.16 1.000 0.901
SF6D 0.63 0.06 0.62 0.06 0.359 0.63 0.06 1.000 0.63 0.05 0.993 1.000
EQ-5D 0.86 0.22 0.84 0.23 0.303 0.85 0.22 1.000 0.87 0.21 0.786 1.000
SF, Short Form Health Survey; SD, standard deviation; VEINES-QoL, Venous Insufficiency Epidemiological and Economic Study. Analyses
were adjusted for baseline differences and for center. Higher values indicate better quality of life. Score scale: EQ-5D, – 0.59 to 1; SF6D and
VEINES-QoLint, 0 to 1. Values in bold indicate statistical significance.
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
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associated with initial compression therapy in any form,
and there is clinically significantly better HRQOL for ini-
tial compression with compression hosiery than for multi-
layer bandaging. Multilayer bandaging is, overall, slightly
more effective than compression hosiery, but without the
gain in HRQOL, and at a significantly higher cost. Com-
pression hosiery is a relatively cheap, easy to use and safe
alternative to multilayer bandaging in all patients. There-
fore, both from both a patient perspective and an eco-
nomic perspective, compression hosiery would be the
preferred choice when initial compression is applied in
unselected patients.
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